Thomas John Charles sold KRYS
May 26, 2026 · Form 4 insider transaction
Thomas John Charles sold 642 shares of Krystal Biotech, Inc. at $302.03 per share, a transaction worth $193.9K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Disposed (sell-side)
Shares
642
Price
$302.03
Total value
$193.9K
InsiderThomas John Charles
Role—
CompanyKrystal Biotech, Inc. (KRYS)
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateMay 26, 2026
Filing dateMay 27, 2026
Shares owned after0
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The sales reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. The Rule 10b5-1 trading plan will terminate on December 31, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.